One of the popular forms of medical specialty, nuclear medicines involves application of radioactive substances in treatment of various diseases and disorders. Also known as, radiopharmaceuticals, these drugs contain radio-emitting ionization radiation and help in diagnosing disease and provide suitable treatment. Accurate identification and treatment of the disease are two major advantage of the nuclear medicine.
Rising demand and evolving technology in the healthcare industry are the strongest driving factors for the global nuclear medicine market, which is aiming at steady growth in terms of revenue and global adoption. Increasing use of SPECT and PET technology for the treatment of the diseases propels market to grow further. Persistent side effects of cancer chemotherapy and radiation therapy are also the driving factors for the market. However, market is constrained by short half life of the radioisotopes which make them difficult to use.
Asia-Pacific nuclear medicine market is segmented by Therapeutic market and Diagnostic market. Both these segments are further categorized based on the types of medicines, their applications and demands. Based on these segments, experts claim that the therapeutic market is mainly dominated by beta emitters for oncology applications. Diagnostic market on the other hand is dominated by radioisotopes such as SPECT and PET . Based on countries, market is segmented into India, China and Japan. Japan is the dominant market for diagnostic radioisotopes with almost 40% share and has around 1,600 gamma cameras. The total number of PET institutes in Japan has increased around 6-7 times in the last 10 years.
Major players in the market are Covidien , IBA Group, Lantheus Medical Imaging, Triad Isotopes, Siemens Healthcare (PETNET Solutions), NTP Radioisotopes.
What makes our report unique?
1) For gaining an exhaustive understanding of the Asia-Pacific nuclear medicine market.
2) Would be of assistance in providing a comprehensive analysis of the major trends and associated prospects for market growth over the coming half a decade.
3) An ideal opportunity for industry consultants, other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
4) Wide-ranging information provided about the leading market players and the major strategies adopted by them.
1.1 Nuclear medicine procedures
1.2 Major nuclear medicine products
1.3 The S-Curve of nuclear medicine
1.4 Market Matrix
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 Definition of radiopharmaceuticals
4. Market Dynamics
4.1 Market Drivers
4.1.1 Increasing incidents of Cancer and Cardiac ailments
4.1.2 Increasing use of SPECT and PET analysis in radiopharmaceuticals
4.1.3 Increasing awareness of radiopharmaceuticals
4.1.4 Public Awareness
4.1.5 Ready availability of radiopharmaceuticals
4.2 Market Constraints
4.2.1 Shorter half life of radiopharmaceuticals
4.2.2 High capiltal investment
4.2.3 Regulatory Guidelines
4.2.4 Reimbursement issues
4.3.1 Potential radioisotopes in pipeline
4.3.2 Increasing neurological applications
4.3.3 Cyclotron based production
4.4.1 Shutdown of Nuclear reactors
5. Asia Pacific Nuclear Medicine Market Segmentation
5.1 Nuclear Medicine Market, By Type of Products
5.1.1 Diagnostic Market
184.108.40.206 SPECT Radioisotopes
220.127.116.11.1 Technetium-99m (TC-99m)
18.104.22.168.2 Thallium-201 (TL-201)
22.214.171.124.3 Iodine (I-123)
126.96.36.199.4 Gallium -67( Ga-67)
188.8.131.52 PET Radioisotopes
184.108.40.206.2 Rubidium-82 (RB-82)
5.1.2 Therapeutic Market
220.127.116.11 Beta Emitters
18.104.22.168 Alpha Emitters
5.2 Asia Pacific Nuclear medicine Diagnostics market, By applications
5.3 Asia Pacific Nuclear Medicine Therapeutic Market, By Application
5.3.2 Bone Metastasis
5.3.4 Endocrine Tumors
5.4 Asia Pacific Country wise segmentation
5.4.3 South Korea
6. COMPETITIVE LANDSCAPE
6.1 Acquisitions and mergers
6.2 New product launch
6.3 Agreements and collaborations
6.4 Market Share Analysis
7. TOP PLAYERS IN THE MARKET
7.2 IBA Group
7.3 Lantheus Medical Imaging
7.4 Triad Isotopes
7.5 Siemens Healthcare (PETNET Solutions)
7.6 NTP Radioisotopes